Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $39 to $44.
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $39 to $44.